Vascular thrombosis occurs commonly in cancer patients. Once the diagnosis of thrombosis is established, it is important to characterize the nature of thrombus, tumoural versus bland, as each have a different prognosis, clinical significance, and management. This review paper discusses the imaging spectrum of tumour thrombus and its clinical significance emphasizing the role of imaging in differentiating tumour from bland thrombus.
Much has been written about venous thromboembolic disease in literature, but data is sparse on tumour thrombus imaging and its implications. Since the time Trousseau described unexpected or migratory thrombophlebitis as a forewarning of occult visceral malignancy, and Virchow described the triad of stasis, hypercoagulability, and vessel wall injury in the late 18th century, as contributing to thrombosis, the association of thrombosis and cancer has come a long way [1, 2] .
Tumour thrombus is important in cancer patients, as affected patients have adverse outcomes and surgical planning is more complex. Incidence of tumour thrombus varies depending on the type of cancer. Malignant involvement of the portal vein in hepatocellular carcinoma (HCC) occurs in approximately 35% of cases, is associated with poorer prognosis and is a contraindication to liver transplantation [3] . Incidence of involvement of inferior vena cava (IVC) in renal cell carcinoma (RCC) is reported to be between 4%-10% of patients [4] . Depending on the level and extent of tumour thrombus in RCC, surgical planning is altered with rates of adverse events proportionately higher depending on the stage of tumour thrombus with complication rates ranging from 12.4%e46.9% [5] .
Identification of tumour thrombosis is challenging, as many patients are asymptomatic, with thrombosis detected on routine staging and follow up scans. Multimodality imaging plays a vital role in the diagnosis of tumour thrombosis using an armamentarium of ultrasound, color Doppler, computed tomography (CT), magnetic resonance imaging (MRI), and combined fluorodeoxyglucose/positron emission tomography/CT (FDG PET/CT) studies.
Imaging
Distinguishing tumour thrombus from bland thrombus is important from a management and prognostic standpoint. A high index of suspicion should be kept when dealing with renal cell carcinoma, hepatocellular carcinoma, and lung and pancreatic cancer, known to be associated with tumour thrombus. Irrespective of the site of origin, certain common features help differentiate malignant from bland thrombus ( Table 1 ). In a subset of patients, both bland and tumour thrombus may coexist [6e8].
Ultrasound and Doppler Findings
Tumour thrombus can be distinguished from bland thrombus by identifying continuity of the tumour with the adjacent vein, abnormal arterial vascularity (low resistance arterial signal), and irregular venous lumen expansion [9, 10] (Figure 1 ). Rossi et al. [11] used contrast-enhanced ultrasonography in the characterization of portal vein thrombosis complicating HCC, using enhancing tissue within the vessel lumen in the early arterial phase. This differentiation is particularly important in HCC patients as tumoural involvement of the portal vein deems patients unsuitable for liver transplantation and often other therapeutic options such as surgical resection and chemoembolization [3, 12] .
An important pitfall to avoid is cavernous transformation of the portal vein since it can be confused with tumour thrombus. Cavernous transformation is evidenced by the development of prominent periportal collaterals with hepatopedal flow, without the presence of venous expansion or a parenchymal mass seen adjacent to the tumoural thrombus [9] (Figure 2 ). Typical patients with cavernous transformation develop portoportal venous channels at the porta hepatis in addition to intrahepatic venous channels and portosystemic collaterals [13] .
CT Findings
An important consideration for the detection of tumoural or bland thrombosis on CT is good bolus of contrast for optimal opacification of the vessel of interest (ie, portal, jugular, renal veins vs IVC/pelvic veins [9] . The hallmark of thrombus on CT is a filling defect within the vessel lumen on contrast-enhanced scans while on unenhanced scans, thrombi are isoattenuating. Indirect signs of thrombosis include dilatation of thrombosed segment, development of collateral pathways, end organ damage, and changes in parenchymal perfusion.
Once the diagnosis of thrombosis is established, it is imperative to distinguish tumour from bland thrombus. While bland thrombi are homogenous and do not enhance ( Figure 3 ), tumour thrombi are typically contiguous with a tumour mass, adherent to the vessel wall, and show variable degrees of enhancement, often similar to the primary mass ( Figures 4-8 ). HCC and RCC tumour thrombi typically demonstrate brisk enhancement in the arterial phase of imaging due to the hypervascular nature of these tumours [14] . Given hypercoagulability associated with malignancy, both bland and tumour thrombi may coexist [14] (Figures 9 and 10).
Tublin et al. [15] in a retrospective study of 58 patients described CT criteria to distinguish between benign and malignant portal vein thrombosis in patients with cirrhosis. Intra thrombus neovascularity, venous expansion (mean main portal vein diameter greater than or equal to 23 mm), and direct invasion of the portal vein were independently diagnostic of malignant portal vein thrombosis.
Occasionally, physiologic circumstances may mimic thrombosis. Mixing of opacified and unopacified blood, especially at the junction of 2 vessels, may give the false impression of clot. Additionally, pseudoenhancement secondary to beam hardening after administration of contrast may mimic thrombosis [9] .
MRI Findings
MRI provides superior soft tissue contrast, is radiation free, and is useful in patients with contraindications to contrast due to availability of flow sensitive sequences. On MRI, bland thrombus appears as a low signal intensity lesion on T2 weighted sequences because of the T2 shortening of blood breakdown products. Tumour thrombus on the other hand shows intermediate to increased signal characteristics on T2 weighted sequences. Similar to CT, tumour thrombus shows enhancement, direct extension from the tumour, and vessel lumen expansion [6] ( Figures 9A, 11-13 ).
Physiologic artifacts may mimic thrombus on MRI. Slow venous flow may increase signal on T2 weighted spin echo and fast spin echo images, mimicking a thrombus. Turbulent and pulsatile flow can cause intraluminal filling defects on time of flight images. Mixing of opacified and unopacified blood causing artifactual filling defects can be confirmed as such on delayed post contrast sequences, on which the filling defects resolve and vessel homogeneity is demonstrated [16] . Diffusion imaging has recently been used to discriminate between malignant and bland thrombus in the portal vein in patients with hepatocellular carcinoma and tumour thrombus. In a study by Catalano et al. [12] on 25 patients, 15 of 19 malignant thrombi showed similar signal intensity as the primary HCC on diffusion weighted images. The ratio of the apparent diffusion coefficients of the thrombus to the apparent diffusion coefficients of the tumour was 0.998 in the malignant group compared with 2.9 in the bland thrombus group (P ¼ .0003).
FDG PET/CT Findings
FDG PET/CT is now an integral part of oncologic imaging, providing both metabolic and anatomical information. Thrombosis may be detected incidentally during a staging scan or may be done to differentiate tumour from bland thrombus. In 2 retrospective series examining tumour thrombus, visual analysis of focal FDG uptake was useful in diagnosing tumour thrombus and no standardized uptake values (SUV) measurements were taken [8] . In a study by Sharma et al. [17] , an SUV max cutoff of 3.63 was used to differentiate tumour from bland thrombus, with sensitivity of 71.4% and specificity of 90%. Lee and Khong [8] used an SUV max of 2.25 as a cutoff to differentiate tumour from bland thrombus, and in conjunction with CE CT characteristics could reliably differentiate these with sensitivity of 78%, specificity of 100%, and accuracy of 88%. An increase Figure 10 . A 50-year-old male with metastatic rectal cancer. Coronal contrast-enhanced computed tomography images show a liver metastasis invading into the inferior vena cava and right atrium (arrow). A more discrete non enhancing bland thrombus is seen in the right atrium (arrowhead). in FDG uptake is due to high metabolic activity within tumour thrombus (Figure 14 ). However, inflammatory or infective thrombi could have similar PET imaging appearances, and, in such cases, CT features are helpful in the diagnosis [8, 18] .
Management
Characterization of tumoural from bland thrombus helps guide management. When tumour thrombus complicates a malignancy being considered for surgical resection, tumour thrombus may be treated with surgical thrombectomy with almost no role of anticoagulation. When patients are deemed poor surgical candidates, other alternatives to treat the tumour including antiangiogenic agents and various interventional radiology guided procedures are attempted.
Imaging is helpful in detecting and delineating the extent of tumour thrombus, therefore aiding in surgical planning. For example, in renal cell carcinoma, if thrombus extends into the IVC beyond the diaphragm, a cardiopulmonary or venous bypass is planned. The tumour is upstaged from T2 to T3 with involvement of the renal veins and T3b with extension into the IVC. Tumoural invasion into the vena cava wall requires resection of the affected segment and vascular reconstruction. There is no role of IVC filter placement in tumour thrombus [4, 19] .
Accurate reporting is paramount, as tumour thrombi are typically underreported and surgical plans may be significantly altered in these cases. In a retrospective study of nonfunctional pancreatic neuroendocrine tumours, surgical planning was altered depending on the tumour thrombus burden, for example, presence of tumour in the portal vein is a contraindication to distal pancreatectomy [20] . In another patient in this series, a more extensive resection than traditional pancreaticoduodenectomy was performed due to a jejunal vein thrombosis [20] .
Interventional radiology and radiation may play a role in the management of hepatocellular cancer with portal vein tumour thrombosis. While portal vein tumour thrombosis has been considered a contraindication to transarterial chemoembolization (TACE) in the past, due to the risk of acute liver failure by such a procedure, a recent report examines the utility of TACE in this setting and demonstrates a survival benefit in TACE-treated patients compared to conservative treatment, 8.67 months versus 1.4 months [21] . Recently, sequential phase 1 and 2 trials using stereotactic body radiotherapy for advanced HCC with malignant thrombus showed sustained local control and higher survival rates as compared to historical controls with a median overall survival of 17 months [22] .
Antiangiogenic agents have been used successfully as neoadjuvant therapy for downsizing tumour thrombus to increase surgical resectability. Antiangiogenic agents have been shown to decrease the malignant tumour thrombus burden as well as the primary tumour burden, though literature is still limited. In a small series of patients with suspected renal cell carcinoma and IVC thrombus, preoperative sunitinib was utilized with some reduction in tumour burden. Bicavital surgery and cardiopulmonary bypass was avoided in 1 patient [23] . At our institution, we have observed tumour thrombus transforming from an enhancing mass to a low attenuating mass after antiangiogenic therapy (Figures 15 and 16 ).
Conclusion
Tumour thrombosis occurs more commonly in renal cell carcinoma, hepatocellular carcinoma, and lung and pancreatic cancer. Traditionally, when feasible, treatment for tumour thrombus is surgical, while medical management is offered for bland thrombus. New approaches are being evaluated in the treatment of tumour thrombus, with increasing use of antiangiogenic agents and a role for interventional radiology. It is essential for the radiologist to be aware of the imaging differences between tumoural and bland thrombus on various imaging modalities to facilitate surgical planning, management and better patient outcomes. 
